HDAC9 and acute myeloid leukemia: Notably, numerous pan-HDAC inhibitors (P-HDACi) such as vorinostat (also known as suberoylanilide hydroxamic acid, SAHA) (112), belinostat (PXD-101) (113), panobinostat (LBH589) (114), pracinostat (MEI Pharma) (115), romidepsin (FK228) (116), and chidamide (CS055, HBI-8000) (117), have been approved by the FDA to treat different cancers, including primary cutaneous T-cell lymphoma, peripheral T-cell lymphoma, MM, and AML.